Literature DB >> 33396736

Sleep Duration in Mouse Models of Neurodevelopmental Disorders.

Rachel Michelle Saré1, Abigail Lemons1, Alex Song1, Carolyn Beebe Smith1.   

Abstract

Sleep abnormalities are common in patients with neurodevelopmental disorders, and it is thought that deficits in sleep may contribute to the unfolding of symptoms in these disorders. Appreciating sleep abnormalities in neurodevelopmental disorders could be important for designing a treatment for these disorders. We studied sleep duration in three mouse models by means of home-cage monitoring: Tsc2+/- (tuberous sclerosis complex), oxytocin receptor (Oxtr) knockout (KO) (autism spectrum disorders), and Shank3 e4-9 KO (Phelan-McDermid syndrome). We studied both male and female mice, and data were analyzed to examine effects of both genotype and sex. In general, we found that female mice slept less than males regardless of genotype or phase. We did not find any differences in sleep duration in either Tsc2+/- or Oxtr KO mice, compared to controls. In Shank3 e4-9 KO mice, we found a statistically significant genotype x phase interaction (p = 0.002) with a trend that Shank3e4-9 KO mice regardless of sex slept more than control mice in the active phase. Our results have implications for the management of patients with Phelan-McDermid syndrome.

Entities:  

Keywords:  Phelan–McDermid syndrome; Shank3; neurodevelopmental disorders; oxytocin receptor; sleep duration; tuberous sclerosis

Year:  2020        PMID: 33396736     DOI: 10.3390/brainsci11010031

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  2 in total

1.  Confirmation of Decreased Rates of Cerebral Protein Synthesis In Vivo in a Mouse Model of Tuberous Sclerosis Complex.

Authors:  Rachel Michelle Saré; Anita Torossian; Inna Loutaev; Carolyn Beebe Smith
Journal:  eNeuro       Date:  2022-07-18

2.  Sleep and Phelan-McDermid Syndrome: Lessons from the International Registry and the scientific literature.

Authors:  Bridgette A Moffitt; Sara M Sarasua; Linda Ward; Diana Ivankovic; Kathleen Valentine; Curtis Rogers; Katy Phelan; Luigi Boccuto
Journal:  Mol Genet Genomic Med       Date:  2022-08-23       Impact factor: 2.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.